An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
SHL Telemedicine (NASDAQ: SHLT) announced its full-year 2023 results, showcasing stable revenue growth and groundbreaking clinical milestones. The company saw a 3.1% increase in total revenues to USD 57.1m, with operations in Israel and Germany contributing to the growth. Adjusted EBITDA was USD 2.1m, with a net loss of USD 6.9m. Strategic developments included advancements in the US direct-to-consumer strategy and successful clinical studies validating the SmartHeart® ECG technology.
Positive
None.
Negative
None.
Insights
The release of SHL Telemedicine's full-year 2023 financial results indicates a controlled revenue increase of 3.1% year-over-year, reflecting steady business operations. However, the adjusted EBITDA decrease to USD 2.1m from USD 3.5m in the prior year highlights a strategic choice to invest in expansion, especially in the US and Germany, despite leading to a short-term contraction in profitability. The net loss widened significantly to USD 6.9m, which may raise concerns among investors about the company's short-term financial health. The operational investments, coupled with non-recurring expenses, are noteworthy as they suggest an underlying transformation in SHL's business structure, potentially offering long-term gains. The cash position remains robust, which provides the company with a buffer for ongoing investments and operational flexibility.
SHL's focus on direct-to-consumer sales in the US and service expansion in Germany signify an aggressive approach to capturing more market share in the telemedicine space. The integration with CVS Minute Clinics and the endorsement through clinical studies from Mayo Clinic and Imperial College London position the company as a pioneer in remote cardiac care. The reported reduction in hospital readmissions (76%) and emergency department visits (41%) underscores the potential efficacy and cost-savings of SHL's SmartHeart® technology. The company's performance in the U.S. Army's Project Convergence further validates the versatility of its solutions. These strategic achievements, while not immediately lucrative, could pave the way for SHL to become a dominant player in telemedicine, provided they translate into widespread adoption and sustainable revenue streams.
The German market is particularly noteworthy for SHL with the Virtual Visits service now accessible to over 12 million insured individuals. The expectation to reach break-even in 2024 is ambitious and will be a important pivot point for the company's profitability in the European sector. The Israeli market remains a solid contributor to SHL's revenue, illustrating resilience even in challenging circumstances such as regional conflicts. The forecast for double-digit profitability growth in Israel for 2024, coupled with the anticipated benefits from previous US investments, paints a positive outlook for revenue and profitability across SHL's diversified operations. Retail investors should monitor the company's ability to leverage its strategic customer relationships and technological advancements to achieve these projections.
TEL AVIV, Israel & ZURICH & NEW YORK--(BUSINESS WIRE)--
SHL Telemedicine Ltd. (NASDAQ: SHLT; SIX Swiss Exchange: SHLTN) ("SHL" or the "Company"), a leading provider and developer of advanced personal telemedicine solutions, announced today its results for the full-year 2023, highlighting fiscally responsible growth across all regions and a strategic focus on expansion and innovation.
In 2023, SHL Telemedicine achieved key highlights, underscoring its global market strength. SHL’s Israel operation maintained stability and profitability, reflecting the company's solid foundation in its home market. In the US, significant advancements were made toward launching direct-to-consumer (B2C) sales of the SmartHeart® ECG platform, enhancing access to remote cardiac care. Additionally, the launch of virtual visit services in Germany, in collaboration with BARMER, marked a significant expansion of SHL's offerings, further demonstrating the company's innovative approach to telemedicine and its commitment to broadening healthcare accessibility.
FY2023 Financial Highlights:
*All comparable previous periods figures are in constant currency1.
Total revenues rose to USD 57.1m, a 3.1% increase from USD 55.4m in 2022.
Revenues from the Company's operation in Israel increased by 2.3% compared to 2022, with revenues standing at USD 42.1m.
Revenues from the Company's operation in Germany amounted to USD 14.1m, a 2.4% increase from USD 13.7m in 2022.
Adjusted EBITDA2 for the Company was USD 2.1m, compared to USD 3.5m in 2022, mainly due to increased investment in Germany and in USA as well as non-recurring expenses of USD 2.2m, related to onetime and restructuring expenses of USD 1.6m in Germany and USD 0.6m Nasdaq® listing expenses.
Cash on hand and short-term cash investments as of December 31, 2023, remain robust at USD 26m.
Net loss was USD 6.9m, compared to a net loss of USD 0.4m in FY2022. The decrease is mainly related to a lower operating profit and to financial expenses due to investor options modifications, which is a non cash item.
Strategic Developments and Highlights:
In the United States, SHL made significant strides in its direct-to-consumer strategy, prioritizing promotion of its SmartHeart® ECG technology. Concurrently, SHL continues to leverage its Tier1 strategic customer relationships, including the integration within CVS Minute Clinics, underscoring SmartHeart's increasing acceptance in the healthcare ecosystem.
In 2023, clinical studies from Mayo Clinic and the Imperial College London showcased SmartHeart®'s unique promise to reduce emergency visits and readmission rates for cardiac patients. The final TELE-ACS findings from Imperial College London study presented at ACC24 and published in JACC, revealed groundbreaking results including a 76% reduction in hospital readmissions and a 41% decrease in ED visits, validating SHL's unique offering in remote cardiac care.
SHL's SmartHeart® technology also excelled in the U.S. Army's Project Convergence – Capstone 4 experiment, showcasing its reliability and advancing military healthcare.
In Israel, SHL's B2C and B2B activities saw growth, with revenues increasing by 2.3% to $42.1m. Despite challenges caused by the war that broke out in the beginning of the 4th quarter, Israel remains highly profitable for SHL.
In Germany, the Doctors' Virtual Visit service launched with BARMER is now available to 12.4 million insured individuals. With a strong growth trend, it's expected to be a key driver for reaching break-even in German operations.
Looking ahead to 2024, the Company expects to see continued growth in revenues with double-digit growth in profitability in their Israel operations; continued consistent growth in the Virtual Visits service in Germany alongside the German operation reaching break even in 2024 and profitability during 2025; Moreover, the company expects to benefit from the investments previously made in the US, both in B2B and B2C activities.
Erez Nachtomy, CEO of SHL, remarked: "The results from 2023 reflect our strategic approach towards stable growth and financial stability amidst the dynamic market landscape. Our achievements in Israel, the advancement of our Virtual Visit services in Germany, and our focused investments in the US market provide the fundament for further growth. Our commitment remains steadfast on driving growth, enhancing financial stability, and meeting our strategic milestones, all while delivering value to our customersand stakeholders and leading the charge in the telemedicine landscape."
Conference Call 4 pm CET / 10 am ET / 5 pm Israel Time
The conference call can be accessed live via the below dial-in numbers:
About SHL Telemedicine
SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957) and on the Nasdaq Stock Exchange (SHLT, ISIN: US78423T2006, CUSIP: 78423T200). For more information, please visit our website at www.shl-telemedicine.com.
Financial calendar
May 9, 2024, Special General Meeting. Tel Aviv, Israel
For more financial information:
For a comprehensive understanding of the Company’s financial reports and related management’s discussion and analysis for applicable periods, please visit the Company’s profile at https://www.sec.gov/edgar or the Company’s full report on its site: www.shl-telemedicine.com/reports
1 Constant currency – to enable meaningful comparison between 2023 and 2022 results, 2022 results are also presented at 2023 exchange rates which are calculated as annual average based on the average monthly exchange rates of each of the USD and the EUR versus the NIS, as published by the Bank of Israel. The management believes that this presentation enables a more meaningful comparison between the periods due to the significant fluctuations in NIS/USD/EUR exchange rates during the period.
2 The Company believes Adjusted EBITDA and Adjusted EBIT provide useful information regarding the Company’s financial and operating performance. Adjusted EBITDA and Adjusted EBIT are not U.S. GAAP measures. You should not construe Adjusted EBITDA and Adjusted EBIT as alternatives to operating profit or cash flows from operating activities determined in accordance with U.S. GAAP or as a measure of liquidity. Adjusted EBITDA and Adjusted EBIT are not defined in the same manner by all companies and may not be comparable to other similarly titled measures of other companies.
Forward Looking Statements:
This announcement contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, specifically Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, are forward-looking statements, including, the Company’s anticipation with respect to changes in its results of operations from prior periods. Readers are cautioned that forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from historical results or any future results expressed or implied by forward-looking statements. Factors that can cause actual results to differ from expectations and those contained in forward-looking statements include those risks described in Item 3.D. "Key Information—Risk Factors" contained in the Company’s Registration Statement on Form 20-F filed with the U.S. Securities Exchange Commission (the "SEC") on March 28, 2023 and in its subsequent filings and submissions with the SEC, including, but not limited to, the Company’s ability to operate and comply with the complex and evolving regulations in the highly regulated healthcare industry; the continued development, consumer acceptance and market adoption of the Company’s products and services in the relatively new, unproven and volatile and rapidly changing telehealth market; the Company’s ability to develop and introduce new products and solutions and enhancements to existing ones; the significant and increasing levels of competition in the telemedicine market; the impacts of COVID-19 and future pandemics and epidemics; the Company’s ability to continue to attract and retain key employees and personal in the highly competitive healthcare industry; the loss or breach of the Company’s proprietary rights and data security and privacy risks; political, judicial, legal, economic and military conditions in Israel and the surrounding region; global economic and financial market conditions and the Company’s ability to adapt to and comply with the different business and market factors, conditions, requirements and laws and regulations in the various countries in which the Company operates internationally; currency fluctuations; labor disputes; the Company’s ability to manage growth and integrate acquired businesses and expanding operations; the Company’s ability to obtain adequate levels of insurance to cover potential losses; the Company’s dependence on key suppliers and sub-contractors and other third parties; and other matters and risks not yet known to the Company or not currently considered material by it. You should not place undue reliance on these forward-looking statements. All written and oral forward-looking statements, attributable to the Company, or persons acting on its behalf, are qualified in their entirety by these cautionary statements. Unless required by law, the Company undertakes no obligation to publicly update or revise any forward-looking statements.
What were SHL Telemedicine's total revenues for full-year 2023?
Total revenues for full-year 2023 were USD 57.1m, a 3.1% increase from the previous year.
What was the net loss for SHL Telemedicine in FY2023?
The net loss for SHL Telemedicine in FY2023 was USD 6.9m, compared to a net loss of USD 0.4m in FY2022.
What strategic developments did SHL Telemedicine focus on in the US?
SHL Telemedicine made significant strides in its direct-to-consumer strategy in the US, promoting its SmartHeart® ECG technology and leveraging Tier1 strategic customer relationships.
What were the key highlights of SHL Telemedicine's operations in Israel in 2023?
SHL Telemedicine's Israel operation maintained stability and profitability, with revenues increasing by 2.3% to $42.1m despite challenges caused by the war.
Where can the Full-Year Report 2023 and presentation be accessed?
The Full-Year Report 2023 and presentation can be accessed on www.shl-telemedicine.com/reports.
